1. Home
  2. PACK vs CHRS Comparison

PACK vs CHRS Comparison

Compare PACK & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ranpak Holdings Corp

PACK

Ranpak Holdings Corp

HOLD

Current Price

$5.62

Market Cap

330.1M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.79

Market Cap

296.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PACK
CHRS
Founded
1972
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
330.1M
296.8M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
PACK
CHRS
Price
$5.62
$1.79
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$6.50
$5.51
AVG Volume (30 Days)
460.8K
945.4K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
1.43
Revenue
$395,000,000.00
N/A
Revenue This Year
$9.29
$73.08
Revenue Next Year
$8.35
$30.94
P/E Ratio
N/A
$1.24
Revenue Growth
7.08
N/A
52 Week Low
$2.91
$0.72
52 Week High
$6.31
$2.62

Technical Indicators

Market Signals
Indicator
PACK
CHRS
Relative Strength Index (RSI) 76.10 51.75
Support Level $5.20 $1.55
Resistance Level $5.83 $1.89
Average True Range (ATR) 0.29 0.10
MACD 0.16 -0.01
Stochastic Oscillator 94.84 33.33

Price Performance

Historical Comparison
PACK
CHRS

About PACK Ranpak Holdings Corp

Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: